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Background: Lipoprotein lipase (LPL) and serum 25-hydroxyvitamin D [25(OH)D] play important roles in the
regulation of lipid metabolism. Although dyslipidemia is associated with insulin resistance (IR) and type 2 diabetes
(T2D), there are limited data available regarding the relationship of LPL and 25(OH)D to IR and T2D at a population
level. The objective of the present study is to investigate the associations of LPL and 25(OH)D with IR and T2D in a
Chinese population.
Methods: The study cohort consisted of 2708 subjects (1326 males, 1382 females; mean age 48.5 ± 12.6 years) in
main communities of Harbin, China. Serum 25(OH)D, LPL, free fatty acids (FFAs), fasting glucose (FG), fasting insulin,
lipid profile, apoA and apoB concentrations were measured.
Results: Serum 25(OH)D concentration was positively associated with LPL (β = 0.168, P < 0.001). LPL was inversely
associated with IR and T2D. Subjects in the lowest quartile of LPL had the highest risk of IR [odds ratio (OR) = 1.85,
95% CI = 1.22-2.68] and T2D (OR = 1.65, 95% CI = 1.14-2.38). Serum 25(OH)D was also inversely associated with IR
and T2D. Vitamin D deficiency [25(OH)D < 20 ng/ml] was associated with an increasing risk of IR (OR = 1.91, 95%
CI = 1.23-2.76) and T2D (OR = 2.06, 95% CI = 1.37-3.24). The associations of 25(OH)D with IR and T2D were
attenuated by further adjustment for LPL.
Conclusions: LPL is associated with serum 25(OH)D, IR and T2D in the Chinese population. These results suggest a
potential mediating role of LPL in the associations of 25(OH)D with IR and T2D.
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Lipoprotein lipase (LPL) is a member of the so-called
lipase superfamily which includes hepatic lipase, pancre-
atic lipase and LPL itself [1]. Although it is mainly
synthesized by the parenchymal cells in adipose, skeletal
and cardiac muscle, LPL has its physiological site of ac-
tion at the capillary endothelial cell surface where the
enzyme catalyzes the lipolysis of triglyceride (TG) to
provide free fatty acids (FFAs) and 2-monoacylglycerol
for tissue utilization [2,3]. Therefore, LPL plays a central
role in lipid metabolism and is widely distributed in various
tissues. In addition to its effect on the lipid metabolism,* Correspondence: sun2002changhao@yahoo.com
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reproduction in any medium, provided the orLPL is also directly or indirectly implicated in some patho-
physiological conditions such as insulin resistance (IR) and
type 2 diabetes (T2D). Reduction of LPL is observed in
patients with T2D and individuals with IR [4-6]. Low LPL
activity accompanied by high TG was observed in diabetic
dyslipidemia [7].
In addition to LPL, vitamin D also plays an important
role in the regulation of lipid metabolism. Over the past
decades, numerous studies have shown that individuals
with vitamin D deficiency are at an increasing risk for a dis-
order of lipid metabolism [8,9]; serum 25-hydroxyvitamin
D [25(OH)D], the main circulating form of vitamin D, is
significantly associated with lipid metabolism [10].
Despite a large body of literature in this regard, the
relationship between LPL and vitamin D is not fully
understood. Existing evidence suggested that treatmentLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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form of vitamin D, could induce the LPL expression in
cells [11]; however, few epidemiological studies have
been so far designed to investigate the association be-
tween vitamin D and LPL at a population level. Fur-
thermore, although it is known that dyslipidemia is
associated with IR and T2D, information is limited on
the association between LPL, 25(OH)D, IR and T2D in
population studies. Importantly the role of LPL in link-
ing 25(OH)D, IR and T2D is largely unknown. The ob-
jective of this cross-sectional epidemiologic study is to
examine the relationship among LPL, 25(OH)D, IR and
T2D in the northeastern Chinese population.
Methods
Study cohort
The source population consisted of 8127 adults, aged
20 to 74 years, who were recruited from main commu-
nities of Harbin, China [12]. In the current study, 3000
individuals (1500 males, 1500 females) were randomly
selected from the source population between August
and October 2008. After 292 subjects were excluded,
the final study sample comprised a total of 2708 sub-
jects (1326 males, 1382 females; mean age 48.5 ±
12.6 years). The exclusion criteria were any disorders
or history known to alter vitamin D metabolism; drug
or alcohol abuse or dependence; severe liver diseases
including hepatitis, cirrhosis, or malignancy; under
regular medication for controlling blood lipids; no
signed informed consent. There were no significant dif-
ferences between participants (2708 subjects) and the
source population (8127 subjects) in age and BMI. De-
sign and all procedures of the present study were in ac-
cordance with the Declaration of Helsinki. This study
was approved by the Ethics Committee of the Harbin
Medical University, and all subjects provided signed
informed consent.
Data collection
Demographic and lifestyle data were obtained using a
general structured questionnaire. Body mass index
(BMI, kg/m2) was calculated as weight in kilograms
divided by the square of the height in meters. The
physical activity level (PAL) was calculated with the for-
mula from the American Institute of Medicine [13].
Blood samples were collected in tubes from each sub-
ject after fasting for 10 hours for laboratory analyses of
study variables. The blood samples were immediately
centrifuged at 2500 g for 15 min to obtain serum which
was instantly cooled down, stored at −80 centigrade.
Fasting serum glucose (FG) and 2-h post-load (75 g
sugar) glucose (PG) for oral glucose tolerance test
(OGTT) were measured quantitatively by the glucose
oxidase method. Concentrations of total cholesterol(TC), high- (HDL) and low-density lipoprotein (LDL)
cholesterols, TG, FFAs, apoA and apoB were assessed
with standard enzymatic methods in an auto-analyzer
(AUTOLAB PM 4000, AMS Corporation, Rome, Italy).
Serum insulin was measured with an auto-analyzer
using commercial kits (Centaur, Bayer Corporation,
Bayer Leverkusen, Germany). LPL concentration in the
post-heparin serum collected in 10 minutes after intra-
venous injection of 30 IU/kg heparin was measured by
enzyme-linked immunosorbent assay (ELISA) using
commercially available ELISA Kits (R&D System, USA).
The inter-assay coefficient and intra-assay coefficient of
LPL were 6.28% and 7.04%, respectively. Homeostasis
model of assessment of insulin resistance (HOMA-IR)
was calculated as HOMA-IR = Fasting glucose (mmol/L) ×
Fasting insulin (mU/L)/22.5. Serum 25(OH)D concen-
trations were determined by ACQUITY Ultra Performance
Liquid Chromatography (Waters, USA). The inter-assay
coefficient and intra-assay coefficient of 25(OH)D at
20 ng/mL were 4.69% and 3.72%, respectively. IR was
defined as HOMA-IR higher than 2.50. T2D was
defined as FG ≥ 7.0 mmol/L, or PG ≥ 11.1 mmol/L on
a 2-h OGTT [14], or a diagnosis of diabetes. Vitamin D
deficiency was defined as serum 25(OH)D concentra-
tions < 20 ng/ml (50 nmol/L), insufficiency 21-29 ng/ml,
and sufficiency ≥ 30 ng/ml (75 nmol/L) [15]. Suboptimal D
status was defined as vitamin D deficiency or vitamin D
insufficiency.Statistical analysis
Characteristics of study variables were presented as
mean ± SD, or median for continuous variables and as
percentage for categorical variables. Log-transformation
was performed to improve normality of the distribution
where necessary. Analysis of covariance (ANCOVA) was
used to assess differences in study variables between
subgroups classified by levels of LPL and 25(OH)D, with
post hoc Bonferroni's correction for multiple compari-
sons. The associations between 25(OH)D and continu-
ous variables such as LPL and FFAs were tested by
multivariable linear regression analysis, adjusted for cov-
ariates (age, sex, BMI, PAL, smoking and alcohol use).
The associations of serum 25(OH)D and LPL with IR
and T2D were tested by logistic regression analysis,
adjusted for the above covariates. In order to evaluate
the influence of individual covariates (age, sex, BMI,
PAL, smoking and alcohol use) on the association para-
meters (ORs), logistic regression models were performed
separately by excluding the covariates one by one from
the model and including the remaining variables. The
changes in OR values reflect the influence of the variable
removed from the model on the particular association.
Statistical analyses were performed with SPSS software
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was considered statistically significant.Results
Characteristics of study variables
The characteristics for study variables are shown in
Table 1 by sex groups. Mean serum 25(OH)D concentra-
tion of the total sample was 25.4 ± 6.5 ng/ml. The preva-
lence of suboptimal vitamin D (vitamin D deficiency and
insufficiency), IR and T2D in 2708 subjects was 74.7%,
19.5% and 15.9%, respectively.Table 1 Demographic and clinical characteristics for




Age, y 47.6 ± 11.3 49.4 ± 13.1 <0.001
BMI, kg/m2 25.7 ± 3.8 25.2 ± 3.3 0.002
Physical activity level 1.45 ± 0.40 1.49 ± 0.42 0.011
Insulin Resistance, n (%) 288 (21.7) 240 (17.4) 0.004
Type 2 diabetes, n (%) 243 (18.3) 189 (13.7) <0.001
Obesity, n (%) 273 (20.6) 283 (20.5) 0.943
Alcohol use, n (%) 797 (60.1) 170 (12.3) <0.001
Smoking, n (%) <0.001
Never 541 (40.8) 1273 (92.1)
Past 164 (12.4) 23 (1.7)
Current 621 (46.8) 86 (6.2)
Clinical variables
25(OH)D, ng/ml 25.7 ± 6.7 25.1 ± 6.4 0.017
FG, mmol/L 5.1 (3.6-9.2) 4.9 (3.4-10.3) 0.054
PG, mmol/L 7.9 (3.8-14.5) 7.6 (3.5-13.6) 0.011
HbAlc, % 4.3 (3.4-11.7) 3.9 (3.3-11.5) 0.002
Insulin, mU/L 6.1 (1.5-17.5) 6.0 (1.4-16.8) 0.051
HOMA-IR 1.4 (0.3-6.2) 1.3 (0.3-6.0) 0.011
TC, mmol/L 4.8 ± 1.1 4.9 ± 1.2 0.024
TG, mmol/L 1.7 (0.5-6.1) 1.5 (0.4-5.9) <0.001
HDL-C, mmol/L 1.5 (0.8-2.3) 1.5 (0.7-2.4) 0.286
LDL-C, mmol/L 3.0 (0.6-5.2) 2.9 (0.5-5.4) 0.118
apoA, mmol/L 1.8 ± 0.4 2.0 ± 0.4 <0.001
apoB, mmol/L 0.8 ± 0.2 0.7 ± 0.3 <0.001
FFAs, μmol/L 723.8 ± 293.7 729.4 ± 265.4 0.602
LPL, U/L 653.1 ± 187.8 664.3 ± 193.5 0.127
a Data are presented as n(%), means ± SD or median (range). χ2 test or ANOVA
were adopted to compare differences between males and females.
Abbreviations: FFAs, free fatty acids; FG, fasting serum glucose; HOMA-IR,
Homeostasis model of assessment - insulin resistance; LPL, lipoprotein lipase;
PG, 2 h post-load glucose; TC, total cholesterol; HDL-C, high-density
lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG,
triglyceride.Differences in variables among quartiles of LPL
Table 2 shows differences in study variables among LPL
quartile groups. BMI values and prevalence of obesity
decreased with increasing LPL quartiles, but the trend
was borderline significant. All metabolic variables had
significantly increasing or decreasing trends across LPL
quartile groups except for insulin, TC and apoB. LDL-C
had a marginally significant decreasing trend across LPL
quartile groups (P = 0.068).
The association of serum 25(OH)D with LPL and other
metabolic variables
The effects of 25(OH)D and LPL on metabolic variables
were further examined with ANCOVA as summarized in
Table 3. After adjusted for age, sex, BMI, PAL, smoking
and alcohol consumption, subjects with vitamin D defi-
ciency indicated significant differences in metabolic vari-
ables compared with vitamin D sufficiency group except
for insulin, TC, LDL-C and apoB. In subjects with vitamin
D insufficiency, selected metabolic variables had significant
differences when compared with vitamin D sufficiency
group. Of interest, subjects in both vitamin D deficiency
and insufficiency groups had significantly lower LPL values
than those in vitamin D sufficiency group (P < 0.05).
In multivariable linear regression analysis model 1,
with 25(OH)D as the independent variable, adjusted for
the same confounding factors in ANCOVA above, 25
(OH)D was significantly associated with all metabolic
variables except for TC, LDL-C and apoB, and margin-
ally associated with insulin (P = 0.051). In regression
model 2, inclusion of LPL did not substantially change
the regression parameters; however, the association be-
tween TG and 25(OH)D was weakened when LPL was
included in model 2.
The relationship of vitamin D and LPL to IR and T2D
Table 4 presents association parameters (OR and 95%
CI) of serum 25(OH)D and LPL with IR and T2D from
logistic regression models. In model 1, subjects with
vitamin D deficiency were 1.91 and 2.06 times more
likely to develop IR and T2D, respectively. In model 2
these association parameters were attenuated by the in-
clusion of LPL which was positively associated with
serum 25(OH)D. Lower LPL was significantly associated
with a higher risk of IR and T2D. The associations be-
came stronger with decreasing quartiles of LPL. Com-
pared with subjects in the top LPL quartile group, the
risk was 1.85 times higher for IR and 1.65 times higher
for T2D among those in the bottom LPL quartile group.
The effects of demographic and lifestyle variables on
association parameters
In the evaluation analysis of the influence of individual
covariates (age, sex, BMI, PAL, smoking and alcohol
Table 2 Characteristics of study variables by lipoprotein lipase quartile groups a
Quartiles of LPL (U/L)
Q 1 (< 532.8) Q 2 (532.9 - 653.2) Q 3 (653.3 - 778.6) Q 4 (> 778.6) P
N 677 677 677 677
Basic characteristics
Age, y 49.2 ± 12.6 47.9 ± 12.3 48.3 ± 10.1 48.6 ± 11.4 0.213
BMI, kg/m2 25.6 ± 3.8 25.2 ± 3.5 25.3 ± 3.6 25.1 ± 3.1 0.053
Physical activity level 1.49 ± 0.39 1.46 ± 0.47 1.50 ± 0.44 1.47 ± 0.38 0.283
Obesity, n (%) 158 (23.3) 142 (21.0) 135 (19.9) 121 (17.9) 0.093
Metabolic variables
25(OH)D, ng/ml 23.1 ± 6.7 24.6 ± 6.3 26.4 ± 6.2 27.8 ± 7.1 <0.001
FG, mmol/L 5.2 (3.5-11.5) 5.0 (3.3-10.8) 4.9 (2.8-10.7) 4.9 (3.0-11.2) 0.021
PG, mmol/L 8.0 (3.6-13.3) 7.7 (3.5-12.7) 7.6 (3.1-12.1) 7.4 (3.0-12.4) 0.008
HbAlc, % 4.3 (3.2-11.9) 4.2 (3.3-12.5) 4.0 (3.2-11.4) 3.9 (3.2-11.7) <0.001
Insulin, mU/L 6.0 (1.4-17.6) 5.8 (1.5-17.9) 5.9 (1.6-17.7) 5.8 (1.4-18.1) 0.149
HOMA-IR 1.5 (0.3-6.6) 1.4 (0.4-6.4) 1.4 (0.2-6.0) 1.3 (0.3-5.9) <0.001
TC, mmol/L 4.8 ± 1.2 4.7 ± 1.1 4.9 ± 1.3 4.8 ± 1.2 0.201
TG, mmol/L 1.9 (0.6-6.2) 1.8 (0.5-6.0) 1.5 (0.7-5.6) 1.5 (0.6-5.9) <0.001
HDL-C, mmol/L 1.4 (0.7-2.1) 1.4 (0.6-2.4) 1.5 (0.7-2.3) 1.5 (0.8-2.5) 0.032
LDL-C, mmol/L 3.0 (0.7-5.3) 3.0 (0.6-5.1) 2.9 (0.5-4.9) 2.9 (0.5-5.2) 0.068
apoA, mmol/L 1.9 ± 0.4 1.9 ± 0.5 2.0 ± 0.4 2.1 ± 0.5 <0.001
apoB, mmol/L 0.8 ± 0.2 0.8 ± 0.3 0.8 ± 0.2 0.8 ± 0.3 0.470
FFAs, μmol/L 776.4 ± 293.2 741.3 ± 295.4 713.2 ± 289.7 685.4 ± 278.5 <0.001
a Data are presented as n(%), means ± SD or median (range). χ2 test or ANOVA were adopted to compare the difference among LPL quartile groups.
Abbreviations: FFAs, free fatty acids; FG, fasting serum glucose; LPL, lipoprotein lipase; PAL, Physical activity level; PG: 2 h post-load glucose; TC, total cholesterol;
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride.
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BMI showed a marked influence on the association of
vitamin D with IR and T2D. Other covariates did not
substantially affect the OR values.
Discussion
Among 2708 northeastern Chinese adults in the current
study, the main findings were that LPL was positively
associated with serum 25(OH)D concentration; LPL and
serum 25(OH)D concentration were inversely associated
with the prevalence of IR and T2D; whereas the associa-
tions of 25(OH)D with IR and T2D were attenuated by
further adjusted for LPL. To the best of our knowledge,
this is the first epidemiological study reporting the asso-
ciation between serum 25(OH)D and LPL in the Chinese
population.
Vitamin D and type 2 diabetes
The rapid economic development has been accompanied
by westernization of lifestyle behaviors and an increasing
epidemic of obesity and metabolic syndrome in China
during the past couple of decades. Consequently, the in-
cidence and prevalence of T2D has been rapidly rising
and has become a major public health problem in Chinaas well as in developed countries [16-18]. Previous sur-
vey indicated the prevalence of T2D is 8.8% in the
source population (n=8940) recruited in Harbin, China
[19]. In the present study cohort, the percentage of T2D
is 15.9%. Different source population size and the exclu-
sion of 292 non-diabetic subjects from the present study
accounted for the difference in the two prevalence rates.
Furthermore, the sampling bias may partially explain the
difference.
Individuals with low serum 25(OH)D concentration
are at increasing risk for dyslipidemia, IR and T2D [20-22].
However, the relationship between vitamin D status
and metabolic syndrome needs to be further investi-
gated since the results from previous studies are con-
troversial. For instance, studies of the British Cohort
and nationally representative sample of the U.S. popu-
lation both reported an inverse association between
serum 25(OH)D concentration and metabolic syndrome
[21,23], but another study in obese population did not
find such a association [24]. Considering a strong link
between diabetes and metabolic syndrome, the inverse
association between 25(OH)D and T2D observed in
our study supported the notion that vitamin D is asso-
ciated with metabolic syndrome.




Serum 25 (OH)D statusa Regression model 1b Regression model 2c
Deficiency (<20 ng/ml) Insufficiency (20-29 ng/ml) Sufficiency (>30 ng/ml) β P β P
Subjects (n) 422 1602 684
FG, mmol/L 5.3 (3.6-11.5)* 5.0 (3.1-9.3) 4.9 (2.7-8.8) −0.086 0.011 −0.055 0.034
PG, mmol/L 8.5 (3.7-13.9)* 7.8 (3.5-12.4) 7.7 (3.2-12.1) −0.091 0.002 −0.058 0.027
HbAlc, % 4.4 (3.3-11.5)** 4.2 (3.2-11.8)** 4.0 (3.3-11.6) −0.120 <0.001 −0.082 0.012
Insulin, mU/L 5.9 (1.5-16.9) 6.1 (1.4-17.8) 6.0 (1.6-18.1) −0.045 0.051 −0.042 0.058
HOMA-IR 1.5 (0.3-6.5)** 1.4 (0.3-6.1)* 1.3 (0.3-5.8) −0.127 <0.001 −0.048 0.047
TC, mmol/L 5.0 ± 1.2 4.8 ± 1.3 4.8 ± 1.2 −0.014 0.532 −0.015 0.525
TG, mmol/L 1.8 (0.8-6.3)* 1.6 (0.5-6.1) 1.5 (0.6-5.8) −0.093 0.001 −0.043 0.056
HDL-C, mmol/L 1.4 (0.7-2.2)* 1.5 (0.8-2.4) 1.5 (0.8-2.3) 0.117 <0.001 0.084 0.011
LDL-C, mmol/L 3.0 (0.8-5.3) 2.9 (0.7-5.2) 2.9 (0.5-5.5) −0.021 0.431 −0.018 0.513
apoA, mmol/L 1.9 ± 0.4* 2.0 ± 0.4 2.0 ± 0.3 0.089 0.005 0.052 0.028
apoB, mmol/L 0.8 ± 0.2 0.8 ± 0.3 0.8 ± 0.2 0.024 0.353 0.022 0.358
FFAs, μmol/L 778.6 ± 284.8** 734.5 ± 306.4* 672.8 ± 297.5 −0.145 <0.001 −0.077 0.021
LPL, U/L 615.3 ± 192.4** 658.8 ± 196.6* 691.2 ± 194.1 0.168 <0.001 NA NA
a Means ± SD or medians ( range). * P < 0.05, ** P < 0.01, compared with vitamin D sufficiency group by ANCOVA, adjusted for age, sex, BMI, physical activity
level, smoking and alcohol consumption.
b Multivariable linear regression analyses model 1, with 25(OH)D concentration as the independent variable, adjusted for age, sex, BMI, physical activity level,
smoking and alcohol consumption.
c Multivariable linear regression analyses model 2, with 25(OH)D concentration as the independent variable adjusted for covariates in model 1 + LPL.
Abbreviations: FFAs, free fatty acids; FG, fasting serum glucose; LPL, lipoprotein lipase; PAL, Physical activity level; PG: 2 h post-load glucose; TC, total cholesterol;
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride; β, regression coefficients.
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T2D could be explained by its direct effect on insulin ac-
tion. 1,25(OH)2D enhances insulin responsiveness for
glucose transport by stimulating the expression of insu-
lin receptor in peripheral tissue [25]. Besides, supple-
mentation of vitamin D in experimental diabetic models
significantly improved the concentration and integrity of
the elastic lamellae in the medial layer of the aorta, andTable 4 Associations of serum 25(OH)D and LPL with IR and T
25(OH)D (ng/ml)
Deficiency Insufficiency Sufficiency
(< 20.0) (20.1-29.9) (≥ 30.0)
IR, OR (95% CI)
Cases/Non-cases 101/321 324/1278 103/581
Model 1 1.91 (1.23-2.76) 1.42 (1.04-1.87) 1.00 (reference)
Model 2 1.35 (1.12-2.45) 1.13 (1.02-1.82) 1.00 (reference)
T2D, OR (95% CI)
Cases/Non-cases 87/335 269/1333 76/608
Model 1 2.06 (1.37-3.24) 1.57 (1.12-2.29) 1.00 (reference)
Model 2 1.42 (1.09-2.68) 1.10 (1.03-1.93) 1.00 (reference)
Model 1, adjusted for age, sex, BMI, PAL, smoking and alcohol consumption.
Model 2, adjusted for covariates in model 1 + LPL.
25(OH)D, 25-hydroxyvitamin D; IR, insulin resistance; T2D, type 2 diabetes; LPL, lipopprevented fragmentation of elastic fibers in the aortic
media [26].
Recently, a prospective intervention study indicated
that 18 months vitamin D supplementation on adult
patients with T2D significantly improved lipid profile
with a favorable change in HDL/LDL ratio [27]. Con-
sidering that significant associations between serum 25
(OH)D and lipid profile such as TG and HDL were also2D
Quartiles of LPL (U/L)
Q 1 Q 2 Q 3 Q 4
(≤ 532.8) (532.9-653.2) (653.3-778.6) (> 778.6)
159/518 143/534 128/549 98/579
1.85 (1.22-2.68) 1.51 (1.03-2.25) 1.32 (0.91-1.93) 1.00 (reference)
NA NA NA NA
124/553 113/564 101/576 94/583
1.65 (1.14-2.38) 1.41 (1.07-2.25) 1.29 (0.84-1.96) 1.00 (reference)
NA NA NA NA
rotein lipase; PAL, physical activity level.
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lipid metabolism may partially mediate the pathogen-
esis of IR and T2D caused by vitamin D deficiency.
Therefore, LPL was introduced and investigated due to
its primary role in the overall lipid metabolism.
LPL linking vitamin D and type 2 diabetes
As a major enzyme responsible for lipolysis of circulat-
ing lipoproteins, LPL can be activated by PPAR through
agonists, and inactivated by angiopoietin-like protein 4
[28]. Research carried out in the population over the
past few years suggested an inverse association between
LPL and TG [29]. Despite the fact that capillary endo-
thelial cell surface is the physiological site of LPL-
mediated hydrolysis reaction, adipose tissue is one of the
most dominant sites for the synthesis of LPL [2,30].
Previous in vitro studies have shown that incubation
with 1,25(OH)2D significantly increased LPL activity and
mRNA in cultured adipocytes [31] and induced LPL ex-
pression in 3 T3-L1 cells [11]. If in vivo studies showed
a similar effect of 1,25(OH)2D on LPL expression, it
would be helpful to investigate the role of LPL in the as-
sociation between vitamin D and glucose-lipid metabol-
ism. Serum 25(OH)D concentration was positively
associated with LPL in the present study. This result is
helpful to explain the inverse association between serum
25(OH)D and TG, since hydrolysis reaction mediated byFigure 1 Putative scheme of effect of vitamin D on insulin resistance
pathogenesis of insulin resistance and type 2 diabetes by direct effect such
such as aberrant calcium flux. Reductive serum 25(OH)D concentration was
which might be associated with insulin resistance and type 2 diabetes.LPL will result in a decrease of TG in serum (Figure 1).
Although supported by previous in vitro studies, the
observed association between 25(OH)D and LPL in this
population still needs to be confirmed in other studies.
Additionally, LPL was found to be inversely and inde-
pendently associated with IR and T2D in the present
study. Since further adjusted for LPL markedly attenu-
ated the associations of 25(OH)D with IR and T2D, the
finding suggested that associations of 25(OH)D with IR
and T2D might be partially mediated by LPL. Certainly,
further studies are needed to clarify this concept.
Serum FFAs concentration was also introduced in the
present study. It is well established that abnormality of
serum FFAs concentration plays an important role in
the pathological incidence and development of IR and
T2D, but data on the association between serum 25(OH)
D and FFAs at a population level are still limited. In our
study, serum 25(OH)D was inversely associated with
FFAs even after adjusted for confounding factors. Despite
the unknown mechanisms, previous in vitro studies
provided the following two aspects to explain the asso-
ciation between 25(OH)D and FFAs. Firstly, activation
of PPAR-δ by 1,25(OH)2D [32] will induce decreased
FFAs concentrations because of increased fat oxidation
and utilization of fatty acids by skeletal muscle [33];
secondly, treatment with 1,25(OH)2D could result in
promotion of fatty acid synthesis and inhibition ofand type 2 diabetes. Vitamin D deficiency influences the
as decreased binding to vitamin D receptor (VDR), and indirect effect
accompanied with decreased LPL and increased TG in our study,
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FFAs concentration was increased under vitamin D de-
ficiency status.
Prevalence of suboptimal vitamin D
High prevalence of suboptimal vitamin D has been a
worldwide health problem. It is estimated that at least
30% of the general population in North America, Europe,
Asia and Australasia has vitamin D deficiency [36].
However, Data from epidemiologic studies with large
samples in northeastern China are still limited in this
regard. Due to the high latitude of northeastern China,
sunshine in this area is relatively inadequate, thus resi-
dents living in this area are at high risk of vitamin D
deficiency [37]. According to the findings from previ-
ous survey [37], a majority of northeastern Chinese
adults (>70%) was estimated to be in suboptimal vita-
min D status. It is well known that the season when
blood is collected is one of the influencing factors of
vitamin D concentration. In the current study, all
serum samples were collected between August and
October when the sunshine is relatively abundant in
this area. A comparison study on vitamin D concentra-
tions in different seasons may provide more informa-
tion in the northeastern area in China.
Limitations and strengths
The present study is cross-sectional in nature; therefore
the causal relationships between serum 25(OH)D, LPL,
IR and T2D cannot be examined. Furthermore, LPL ac-
tivity was not measured. The main strength of the
present study is that the study cohort is representative
of the source population with a large sample size. This is
the first epidemiological study investigating the associa-
tions of serum LPL with 25(OH)D, IR and T2D in the
population in China.
Conclusions
The present study indicates that LPL is significantly
associated with serum 25(OH)D, IR and T2D, adjusted
for confounding factors. The associations of 25(OH)D
with IR and T2D may be partially mediated by changes
in LPL concentrations. Further in vivo, vitro and popula-
tion studies are needed to replicate the findings from the
current study.
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